UBS Group
TDACW

UBS Group’s Translational Development Acquisition Corp Warrants TDACW Stock Holding History

UBS Group’s Portfolio TDACW Stock Details TDACW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128 Hold
1,067
– – ﹤0.01% 10094
2025
Q4 		$299 Sell
1,067
-732
-41% -$240 ﹤0.01% 10049
2025
Q3 		$522 Sell
1,799
-716
-28% -$194 ﹤0.01% 9641
2025
Q2 		$581 Sell
2,515
-225
-8% -$47 ﹤0.01% 9789
2025
Q1 		$384 Buy
+2,740
New +$482 ﹤0.01% 9798

Other funds holding TDACW

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

UBS Group's TDACW Position: Q1 2026 in Review

UBS Group held its Translational Development Acquisition Corp Warrants (TDACW) position steady in Q1 2026 at 1,067 shares worth $128. The position accounts for ﹤0.01% of the portfolio, ranked #10094.

UBS Group first reported a position in TDACW in Q1 2025 and has held it in 5 quarters since. The position peaked at $581 in Q2 2025. 32 funds tracked by Wall St. Rank hold TDACW as of Q1 2026.

  • UBS Group held 1,067 shares of Translational Development Acquisition Corp Warrants worth $128 as of Q1 2026.
  • UBS Group left its Translational Development Acquisition Corp Warrants share count unchanged in Q1 2026.
  • Translational Development Acquisition Corp Warrants made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10094 holding.
  • UBS Group first reported a position in Translational Development Acquisition Corp Warrants in Q1 2025 and has held it in 5 quarters since.
  • UBS Group's Translational Development Acquisition Corp Warrants position peaked at $581 in Q2 2025.
  • 32 funds tracked by Wall St. Rank held Translational Development Acquisition Corp Warrants as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.